With drugs being approved faster in the last twenty years, BBWs have also increased. (In 2013, the FDA reversed its decision and lifted some of the prescribing and dispensing restrictions for rosiglitazone.) They conclude that the warnings were not warranted. The dataset consisted of a retrospective cohort of over half a million patients with diabetes from 2003-2008 this resulted in close to 10 million observations, a far larger sample than previously used studies by the FDA. The authors evaluated the above-mentioned FDA warning using a large and unique dataset from U.S. We suggest the FDA continue to follow their practices using meta-analysis and post-marketing surveillance to detect adverse events like heart attack, for example, but use caution before jumping the gun. This is a complementary approach, a thought process which can be used to further investigate."Īhuja explains, "Regulatory agencies like the FDA, the Bureau of Consumer Protection, and those related to transportation safety, value erring on side of caution. "Or if a drug already has a warning, continuously monitor it, like every six months to affirm the decision. "Use data in a sophisticated manner to catch adverse events, but validate what you find about the drug using data," suggests Ahuja. The authors say, "Deficiencies exist in the process of collecting, reviewing, and analyzing the evidence used to issue BBWs, highlighting a gap in evidence-based medicine." By using large data sources in novel ways, such as observational studies, and advanced analytics, better pharmacovigilance can be achieved. It can be used retrospectively to evaluate a warning that has already been issued or a prospectively to determine whether a drug deserves a BBW. An evidence-based decision support system that the authors coined as "Data Analytics for Robust and Enhanced Drug Decision-making" or DAREDD, employs "big data" in a sophisticated manner. Their proposed template for regulatory agencies can be used to assess associations between a drug and specific adverse reactions of interest. The authors' approach is complementary to the FDA's existing detection systems. economy has benefitted immensely from new blockbuster drugs coming onto the market by firms competing." "Diabetes drugs are a very large market, and the U.S. adult population has prediabetes," says Ahuja. "We studied this drug because of the high prevalence of the disease – roughly 10% of Americans have diabetes and another third of the U.S. The BBW followed a publication that showed, using meta-analysis of past clinical trials, rosiglitazone to be associated with a 43% increased risk of heart attack and a 64% increased risk of cardiovascular mortality. Manufactured by GlaxoSmithKline, rosiglitazone belongs to a class of medications widely used to lower blood glucose in patients with type 2 diabetes. The authors studied a controversial black box warning in 2007 on a diabetes drug, rosiglitazone, marketed as "Avandia," that led to large declines in the drug's use. The Food and Drug Administration (FDA) issues black box warnings (BBWs), its most stringent, to signify that a drug or device carries a significant risk of serious or life-threatening adverse effects. Additionally, this new approach using big data demonstrates how regulatory agencies can advance their governance missions by monitoring public safety with more robust, real-time analytical methods. In a first-of-its-kind study, SMU Cox ITOM Professor Vishal Ahuja and co-authors show how the use of data can validate life-changing health care findings. The use of big data in the health care industry, the largest sector of the economy, offers many benefits for the overall economy, businesses, and the health and well-being of people.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |